MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Belite Bio Inc. ADR (NASDAQ: BLTE)*
Organization & Developments: Belite Bio
Parents
Belite Bio Inc. ADR (NASDAQ: BLTE)*
Children
*Clinical stage biopharma targeting untreatable age-related metabolic disease.
*Pipeline of novel therapies, which is built on our RBP4 (Retinol Binding Protein 4) IP Portfolio, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.
2024: Belite Bio: Interesting Science, But Quite A Few Worries
2025: Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout
2025: Belite Bio: The Picture Is Still Unclear
Jumps
Finance & Acquisitions: Belite Bio
Key People: Belite Bio